Total amount: € 0,00
Official Journal of the Italian Society of Dermatology and Sexually Transmitted Diseases
Indexed/Abstracted in: EMBASE, PubMed/MEDLINE, Science Citation Index Expanded (SciSearch), Scopus
Impact Factor 1,014
Online ISSN 1827-1820
CUTANEOUS MALIGNANCY UPDATE: MELANOMA IN 2007
Roesch A., Vogt T.
Department of Dermatology Regensburg University Medical Center, Regensburg, Germany
Melanoma is the most lethal of human skin cancer and its incidence is increasing worldwide. Melanomas often metastasize early during the course of the disease and are then almost intractable by current therapeutic regimens. Consequently, understanding the factors that maintain melanocyte homeostasis and prevent their neoplastic transformation into melanoma is of outstanding interest. Targeted molecular therapeutics are tailored to genetic abnormalities that are associated with tumor progression. In this review, we report about our quest for new diagnostic biomarkers and therapeutic targets, respectively, using different molecular techniques and approaches, including cDNA microarrays, RT-PCR, conventional immunohistochemistry and tissue-microarrays from in vivo and in vitro samples. We will describe our recent findings on the newly discovered markers in detail, among them phosphorylated pRb Ser795, the retinoblastoma protein binding protein 2-homolog 1 (RBP2-H1) and the dipeptidyl peptidase IV (DPPIV), and link them to already known mechanisms of melanoma pathogenesis. Since the reported markers may be causally linked to malignant transformation, their molecular signaling mechanisms deserve to be studied in more detail in future investigations.